These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 28180225)

  • 1. Rediscovering the octapeptins.
    Velkov T; Roberts KD; Li J
    Nat Prod Rep; 2017 Mar; 34(3):295-309. PubMed ID: 28180225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. History, Chemistry and Antibacterial Spectrum.
    Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
    Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
    Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic combinations of polymyxins.
    Lenhard JR; Nation RL; Tsuji BT
    Int J Antimicrob Agents; 2016 Dec; 48(6):607-613. PubMed ID: 27865626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
    Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
    ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octapeptin C4 and polymyxin resistance occur via distinct pathways in an epidemic XDR Klebsiella pneumoniae ST258 isolate.
    Pitt ME; Cao MD; Butler MS; Ramu S; Ganesamoorthy D; Blaskovich MAT; Coin LJM; Cooper MA
    J Antimicrob Chemother; 2019 Mar; 74(3):582-593. PubMed ID: 30445429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
    Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria.
    Doymaz MZ; Karaaslan E
    Infect Dis (Lond); 2019 Sep; 51(9):676-682. PubMed ID: 31298061
    [No Abstract]   [Full Text] [Related]  

  • 9. Probing the penetration of antimicrobial polymyxin lipopeptides into gram-negative bacteria.
    Deris ZZ; Swarbrick JD; Roberts KD; Azad MA; Akter J; Horne AS; Nation RL; Rogers KL; Thompson PE; Velkov T; Li J
    Bioconjug Chem; 2014 Apr; 25(4):750-60. PubMed ID: 24635310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
    Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
    Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules.
    Schneider-Futschik EK; Paulin OKA; Hoyer D; Roberts KD; Ziogas J; Baker MA; Karas J; Li J; Velkov T
    ACS Infect Dis; 2018 May; 4(5):646-655. PubMed ID: 29566483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens.
    Roberts KD; Zhu Y; Azad MAK; Han ML; Wang J; Wang L; Yu HH; Horne AS; Pinson JA; Rudd D; Voelcker NH; Patil NA; Zhao J; Jiang X; Lu J; Chen K; Lomovskaya O; Hecker SJ; Thompson PE; Nation RL; Dudley MN; Griffith DC; Velkov T; Li J
    Nat Commun; 2022 Mar; 13(1):1625. PubMed ID: 35338128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes.
    Han ML; Shen HH; Hansford KA; Schneider EK; Sivanesan S; Roberts KD; Thompson PE; Le Brun AP; Zhu Y; Sani MA; Separovic F; Blaskovich MAT; Baker MA; Moskowitz SM; Cooper MA; Li J; Velkov T
    ACS Infect Dis; 2017 Aug; 3(8):606-619. PubMed ID: 28695731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to polymyxins in Gram-negative organisms.
    Jeannot K; Bolard A; Pl├ęsiat P
    Int J Antimicrob Agents; 2017 May; 49(5):526-535. PubMed ID: 28163137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performances of the Rapid Polymyxin
    Lescat M; Poirel L; Jayol A; Nordmann P
    Microb Drug Resist; 2019 May; 25(4):520-523. PubMed ID: 30508392
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovery of Novel Polymyxin-Like Antibiotics.
    Velkov T; Roberts KD
    Adv Exp Med Biol; 2019; 1145():343-362. PubMed ID: 31364086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
    Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
    Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New polymyxin derivatives that display improved efficacy in animal infection models as compared to polymyxin B and colistin.
    Vaara M
    Med Res Rev; 2018 Sep; 38(5):1661-1673. PubMed ID: 29485690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
    Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
    Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reviving Polymyxins: Achievements, Lessons and the Road Ahead.
    Li J
    Adv Exp Med Biol; 2019; 1145():1-8. PubMed ID: 31364067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.